ClinicalTrials.gg
CompletedNCT05578859Updated Nov 7, 2022

A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects

A Phase 1 interventional study of AMG 510 in Healthy Subjects, sponsored by Amgen. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 7 months ago, and no results have been posted to the registry.
  • Registered 2 years 7 months after the study started (first participant enrolled Mar 2020, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary objectives of the study are: to characterize the primary route(s) of elimination of [14C]-AMG 510 and drug-related material, and estimate the overall recovery of radiolabeled material in healthy male participants after oral administration of [14C]-AMG 510, and to characterize the pharmacokinetic (PK) of total radioactivity and AMG 510 following a single oral dose of [14C]-AMG 510 in healthy male participants.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Healthy volunteers
  • AMG 510
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participants between 18 and 55 years of age (inclusive) at the time of Screening.
  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations as assessed by the Investigator (or designee).
  • between 18 and 30 kg/m2 (inclusive) at the time of Screening.
  • History of a minimum of 1 bowel movement per day.

Exclusion criteria

Exclusion Criteria:

  • History or evidence, at Screening or Check-in, of disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  • History suggestive of esophageal (including esophageal spasm, esophagitis), gastric, or duodenal ulceration or bowel disease (including but not limited to peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease, or irritable bowel syndrome); or a history of gastrointestinal surgery other than uncomplicated appendectomy.
  • Inability to swallow oral medication or history of malabsorption syndrome.
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  • Poor peripheral venous access.
  • History of alcoholism or drug/chemical abuse within 1 year prior to Check-in.
  • Participant has received a dose of an drug (new chemical entity) within the past 90 days or 5 half-lives, whichever is longer, prior to Check-in.
  • Participants with exposure to significant diagnostic or therapeutic radiation (eg, serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in.
  • Participants who have participated in a radiolabeled drug study where exposures are known to the Investigator within the previous 4 months prior to admission to the clinic for this study or participated in a radiolabeled drug study where exposures are not known to the Investigator within the previous 6 months prior to admission to the clinic for this study. The total 12-month exposure from this study and a maximum of 2 other previous radiolabeled studies within 4 to 12 months prior to this study will be within the Code of Federal Regulations (CFR)-recommended levels considered safe, per US Title 21 CFR 361.1: less than 5000 mrem whole body annual exposure with consideration given to the half-lives of the previous radiolabeled study drugs received.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AMG510

    Each participant will receive a single oral dose of AMG510 on Day 1 after an overnight fast.

    Drug: AMG 510

Interventions

  • Single oral dose of AMG510.

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) from time zero to infinity (AUCinf)

    Time frame: Day 1 to Day 14

  2. AUC from time zero to the last quantifiable concentration (AUClast)

    Time frame: Day 1 to Day 14

  3. Maximum observed concentration (Cmax)

    Time frame: Day 1 to Day 14

  4. Time of Cmax (tmax)

    Time frame: Day 1 to Day 14

  5. Apparent terminal elimination half-life (t1/2)

    Time frame: Day 1 to Day 14

  6. Total clearance (AMG 510 only; CL/F)

    Time frame: Day 1 to Day 14

  7. Volume of distribution (AMG 510 only; Vz/F)

    Time frame: Day 1 to Day 14

  8. Plasma AMG 510 to total radioactivity ratio

    Time frame: Day 1 to Day 14

  9. Whole blood to plasma total radioactivity ratio

    Time frame: Day 1 to Day 14

  10. Amount (Aeu) of AMG510 excreted in urine

    Time frame: Day 1 to Day 14

  11. Percentage (feu) of AMG510 excreted in urine

    Time frame: Day 1 to Day 14

  12. Renal clearance (CLR) of AMG510

    Time frame: Day 1 to Day 14

  13. Amount (Aef) of AMG510 excreted in feces

    Time frame: Day 1 to Day 14

  14. Percentage (fef) of AMG510 excreted in feces

    Time frame: Day 1 to Day 14

Secondary outcomes

  1. Metabolite profile of AMG 510

    Time frame: Day 1 to Day 14

  2. Identification of AMG 510 metabolites

    Time frame: Day 1 to Day 14

  3. Incidence of adverse events

    Adverse events will be graded by severity. Laboratory abnormalities (hematology, clinical chemistry, and urinalysis test results) will be recorded as adverse events, in addition to abnormalities in vital signs and physical examinations.

    Time frame: Up to approximately 6 weeks

  4. QTc interval measured by 12-lead electrocardiogram (ECG)

    Time frame: Up to approximately 6 weeks

07

Study locations

1 site
  • Covance Clinical Research Unit, Inc
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Mar 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 13, 2022
StartActual
Mar 11, 2020
Primary completionActual
Mar 24, 2020
CompletionActual
Mar 24, 2020
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05578859
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Mar 11, 2020
Primary completion
Mar 24, 2020
Completion
Mar 24, 2020
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion